Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Mallinckrodt
AstraZeneca
Baxter
Medtronic

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for MYK-461

See Plans and Pricing

« Back to Dashboard

What is the drug development status for MYK-461?

MYK-461 is an investigational drug.

There have been 10 clinical trials for MYK-461. The most recent clinical trial was a Phase 1 trial, which was initiated on May 29th 2018.

The most common disease conditions in clinical trials are Cardiomyopathies, Hypertrophy, and Cardiomyopathy, Hypertrophic. The leading clinical trial sponsors are MyoKardia, Inc. and [disabled in preview].

There are two US patents protecting this investigational drug and twenty-seven international patents.

Recent Clinical Trials for MYK-461
TitleSponsorPhase
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCMMyoKardia, Inc.Phase 2/Phase 3
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic CardiomyopathyMyoKardia, Inc.Phase 3
Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEERMyoKardia, Inc.Phase 2

See all MYK-461 clinical trials

Clinical Trial Summary for MYK-461

Top disease conditions for MYK-461
Top clinical trial sponsors for MYK-461

See all MYK-461 clinical trials

International Patents for MYK-461

Drugname Country Document Number Estimated Expiration Related US Patent
MYK-461 Australia 2014281408 2033-06-21   Start Trial
MYK-461 Australia 2018264088 2033-06-21   Start Trial
MYK-461 Brazil 112015031864 2033-06-21   Start Trial
MYK-461 Canada 2915967 2033-06-21   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Dow
AstraZeneca
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.